UEV1B Antibody

What is UEV1B and what cellular functions does it regulate?

UEV1B (TMEM189-UBE2V1 isoform 2) is a protein involved in the regulation of endosomal sorting and receptor trafficking pathways. Research has demonstrated that UEV1B significantly impacts the degradation of EGF:receptor complexes by strongly colocalizing and associating with ubiquitin and Hrs in endosomes. When overexpressed, UEV1B slows the degradation of EGF:receptor complexes and reduces the efficiency of endosomal sorting by associating with ubiquitinated proteins and Hrs . The B-domain of UEV1B, rather than the UEV-domain, appears to be primarily responsible for these functions, suggesting the presence of a novel endosomal targeting sequence within this region . Understanding UEV1B's role in receptor trafficking is critical for developing effective antibodies that target specific domains of the protein.

How can I distinguish between UEV1A and UEV1B in experimental systems?

Distinguishing between UEV1A (UBE2V1) and UEV1B (TMEM189-UBE2V1 isoform 2) requires careful experimental design due to their sequence similarities. The most effective approach is through subcellular localization studies, as they exhibit different distribution patterns. UEV1B demonstrates strong colocalization with endosomal markers, particularly with ubiquitin and Hrs in endosomes, while UEV1A shows different localization patterns . For immunological detection, antibodies targeting the unique B-domain of UEV1B can provide specificity. Alternatively, using YFP-fusion constructs of the individual proteins allows for visualization of their distinct localization patterns in cells with suitable morphology for microscopic analysis, such as COS1 cells . When conducting Western blot analysis, the size difference between these proteins (due to the additional B-domain in UEV1B) can serve as a distinguishing feature.

What fixation and permeabilization methods are optimal for UEV1B antibody staining?

For optimal UEV1B antibody staining in immunofluorescence experiments, a sequential approach is recommended. Begin with paraformaldehyde fixation (4%, 15-20 minutes at room temperature) to preserve protein localization and cellular architecture. This is particularly important for maintaining the integrity of endosomal structures where UEV1B predominantly localizes. For permeabilization, a gentle detergent such as 0.1% Triton X-100 for 5-10 minutes is generally effective for allowing antibody access to intracellular UEV1B without disrupting its association with endosomal membranes. Alternative approaches include methanol fixation/permeabilization (-20°C for 10 minutes) which can sometimes enhance detection of endosomal proteins. When designing staining protocols, consider that UEV1B strongly colocalizes with ubiquitin and Hrs in endosomes , so dual staining with markers for these proteins can serve as positive controls for successful UEV1B antibody staining and provide validation of proper fixation and permeabilization.

What strategies can overcome cross-reactivity issues with UEV1B antibodies?

Addressing cross-reactivity issues with UEV1B antibodies requires sophisticated approaches based on the principles of antibody specificity. Since UEV1B shares significant sequence homology with other UEV domain-containing proteins, cross-reactivity is a common challenge. To overcome this, implement a biophysics-informed model approach as demonstrated in recent research on antibody specificity . This involves identifying distinct binding modes associated with each potential cross-reactive antigen. Begin by conducting competitive ELISAs to characterize the binding profile of your antibody against UEV1B and related proteins. For highly specific antibody development, utilize phage display selection against the unique B-domain of UEV1B rather than the conserved UEV domain . Additionally, incorporate negative selection steps against related proteins like UEV1A to deplete cross-reactive binders. For validation of existing antibodies, perform systematic epitope mapping to confirm specificity for regions unique to UEV1B, particularly within the B-domain that contains the novel endosomal targeting sequence . Finally, always validate antibody specificity in cells where UEV1B has been knocked down or knocked out to confirm signal specificity.

How can I design experiments to study the interaction between UEV1B, ubiquitin, and Hrs?

Designing rigorous experiments to study the tripartite interaction between UEV1B, ubiquitin, and Hrs requires a multi-faceted approach. Begin with reciprocal co-immunoprecipitation assays using antibodies against each protein component, followed by Western blotting to detect the associated partners. For spatial resolution, implement multi-color confocal microscopy with sequential scanning to minimize bleed-through when visualizing the colocalization of these proteins . Quantify colocalization using Pearson's correlation coefficient and Manders' overlap coefficient to establish statistical significance of associations. To demonstrate direct binding, employ in vitro binding assays with purified recombinant proteins, focusing particularly on the B-domain of UEV1B which has been implicated in mediating these interactions . For functional analysis, establish cells with inducible expression of wild-type or domain-mutated UEV1B and assess how these mutations affect association with ubiquitin and Hrs. Additionally, utilize proximity ligation assays (PLA) to visualize and quantify protein-protein interactions in situ with nanometer resolution. For temporal dynamics, implement live-cell imaging with fluorescently tagged proteins to track the kinetics of complex formation following EGF stimulation.

What are the critical controls for validating UEV1B antibody specificity in immunoblotting and immunoprecipitation?

Validating UEV1B antibody specificity requires implementing a comprehensive set of controls. For immunoblotting, the gold standard negative control is lysate from cells where UEV1B has been knocked out using CRISPR/Cas9 or knocked down via siRNA targeting regions distinct from those recognized by the antibody. Since siRNAs targeting the UEV domain affect multiple genes with sequence identity , design siRNAs specifically targeting the unique B-domain of UEV1B. Positive controls should include lysates from cells overexpressing tagged UEV1B constructs, allowing detection with both UEV1B antibody and tag-specific antibodies. For cross-reactivity assessment, perform parallel blots with recombinant UEV1A, UEV1B, and other related proteins, ensuring your antibody recognizes only UEV1B. For immunoprecipitation validation, conduct reciprocal pull-downs with known interaction partners such as ubiquitin and Hrs . Additionally, perform competition assays where pre-incubation with recombinant UEV1B should abolish antibody binding, while pre-incubation with related proteins should not. Include isotype-matched control antibodies in immunoprecipitation to identify non-specific binding. Finally, validate the antibody across multiple cell lines with varying UEV1B expression levels to ensure consistent detection patterns.

How does UEV1B overexpression impact quantitative proteomic analysis of the endosomal pathway?

UEV1B overexpression significantly reshapes the endosomal proteome through several mechanisms that can be captured and quantified using advanced proteomic approaches. Stable isotope labeling with amino acids in cell culture (SILAC) combined with endosomal fractionation reveals that UEV1B overexpression leads to enrichment of ubiquitinated proteins in endosomal compartments due to its strong colocalization and association with ubiquitin . Quantitative proteomic data typically shows decreased representation of EGFR in late endosomal/lysosomal fractions when UEV1B is overexpressed, consistent with the observed delay in EGF:receptor complex degradation . For accurate interpretation of these proteomic datasets, implement a differential abundance analysis that accounts for shifts in protein localization rather than just total protein levels. When conducting such studies, a critical methodological consideration is the establishment of appropriate fractionation protocols that effectively separate early endosomes, late endosomes, and lysosomes to track protein trafficking through these compartments. Additionally, tandem mass tag (TMT) labeling coupled with mass spectrometry allows for temporal profiling of how UEV1B overexpression alters endosomal cargo progression through the degradative pathway following EGF stimulation.

How do I interpret conflicting results between UEV1B localization studies using antibodies versus tagged constructs?

Conflicting results between antibody-based and tagged construct approaches for UEV1B localization require systematic analysis to resolve. First, evaluate the possibility that the antibody epitope becomes masked when UEV1B forms complexes with interaction partners like ubiquitin and Hrs in endosomes , potentially leading to false-negative staining in certain compartments. Conversely, assess whether the tag on UEV1B constructs might interfere with proper protein folding or interactions, particularly if the tag is proximal to the B-domain that contains the endosomal targeting sequence . To resolve these discrepancies, implement dual detection approaches where UEV1B is visualized simultaneously with both methods in the same cells. Additionally, use truncation constructs to determine if specific domains influence localization patterns differently when tagged versus detected by antibodies. Functional assays, such as measuring EGFR degradation rates, can provide confirmatory evidence for which localization pattern correlates with the established biological activity of UEV1B in slowing EGF:receptor complex degradation . Finally, super-resolution microscopy techniques such as STORM or PALM offer enhanced spatial resolution that may reveal more nuanced localization patterns that resolve apparent contradictions observed with conventional microscopy.

How can I resolve discrepancies in UEV1B antibody performance across different immunological techniques?

Resolving discrepancies in UEV1B antibody performance across different techniques requires a methodical troubleshooting approach addressing technique-specific variables. For Western blotting discrepancies, evaluate how different lysis buffers affect epitope exposure, as the strong association of UEV1B with endosomal membranes may require detergent conditions that differ from optimal immunoprecipitation or immunofluorescence conditions. For immunoprecipitation failures despite successful Western blotting, consider that the antibody may recognize a denatured epitope that is inaccessible in the native conformation, necessitating alternative antibody clones. When immunofluorescence results conflict with biochemical data, systematic testing of fixation and permeabilization protocols is crucial, as these steps significantly impact epitope accessibility in membranous compartments where UEV1B localizes . Consider that some antibodies may recognize specific post-translational modifications of UEV1B that vary across subcellular locations or cellular states. To address this, characterize your experimental system using appropriate controls across each technique, including overexpression of YFP-tagged UEV1B constructs for direct visualization . Additionally, epitope competition assays with recombinant UEV1B protein fragments can identify which regions of the protein are recognized by the antibody under different experimental conditions, providing insight into performance discrepancies.

What are the implications of UEV1B's association with Hrs for designing experiments on EGFR trafficking?

The association between UEV1B and Hrs has profound implications for experimental design when studying EGFR trafficking. Since UEV1B overexpression abrogates the ability of Hrs to colocalize with EGFR , experimental timing becomes critical. Design pulse-chase experiments with precisely defined EGF stimulation intervals to capture the sequential events in receptor trafficking before UEV1B-mediated disruption occurs. When comparing wild-type and UEV1B-overexpressing cells, incorporate multiple time points (5, 15, 30, 60, and 120 minutes post-EGF stimulation) to fully capture the kinetic differences in EGFR trafficking. For mechanistic studies, implement simultaneous visualization of UEV1B, Hrs, and EGFR using spectrally distinct fluorophores to directly observe the competition between UEV1B and EGFR for Hrs association. Consider that traditional bulk biochemical assays may obscure the heterogeneity in endosomal populations affected by UEV1B; therefore, complement these with single-endosome analysis using high-resolution microscopy. When designing genetic interventions, target specific domains of UEV1B, particularly the B-domain responsible for endosomal targeting , to create separation-of-function mutants that distinguish between UEV1B's effects on Hrs versus other potential interacting partners. Finally, incorporate analyses of ubiquitination patterns on both EGFR and endosomal proteins, as the strong association of UEV1B with ubiquitin may affect multiple ubiquitin-dependent sorting steps beyond just Hrs interaction.

How should antibody concentration be optimized for detecting endogenous versus overexpressed UEV1B?

Optimizing antibody concentration for detecting endogenous versus overexpressed UEV1B requires a systematic titration approach with different considerations for each scenario. For endogenous UEV1B detection, begin with a broad concentration range (typically 0.1-10 μg/ml for immunofluorescence or 0.05-1 μg/ml for Western blotting) and assess signal-to-noise ratio. Critical controls must include samples where UEV1B has been knocked down to determine specificity at each concentration. Since UEV1B levels may vary across cell types due to its role in endosomal trafficking , optimize separately for each experimental cell line. For overexpressed UEV1B detection, substantially lower antibody concentrations are typically required to prevent signal saturation. Implement a sequential dilution series at least 5-fold lower than endogenous detection concentrations. When performing dual detection of endogenous and overexpressed UEV1B in the same experiment, consider using differentially tagged secondary antibodies with distinct fluorophores and exposure settings optimized for each expression level. For quantitative comparisons, establish a standard curve using recombinant UEV1B protein to determine the linear detection range of your antibody. Finally, remember that UEV1B's association with endosomal structures may create localized concentrations that appear as punctate staining; optimal antibody concentration should reveal this pattern without creating background in other cellular compartments.

What experimental approaches can distinguish between the roles of UEV1B's UEV domain versus B-domain?

Distinguishing between the functional contributions of UEV1B's UEV domain and B-domain requires a comprehensive domain-based experimental strategy. Design and express a series of domain-deletion constructs: full-length UEV1B, UEV domain-only, B-domain-only, and UEV1A (which naturally lacks the B-domain) . For each construct, assess subcellular localization through immunofluorescence microscopy, focusing particularly on colocalization with endosomal markers such as Hrs and ubiquitin . Implement functional assays measuring EGFR degradation kinetics following EGF stimulation, as UEV1B overexpression has been shown to slow this process . Biochemical fractionation studies can determine which domain is responsible for endosomal association by separating cytosolic from membrane fractions and analyzing the distribution of each construct. For protein-protein interaction analysis, perform co-immunoprecipitation experiments with Hrs and ubiquitinated proteins to determine which domain mediates these associations. To assess structure-function relationships at higher resolution, introduce point mutations in conserved residues within each domain and evaluate their impact on localization and function. Finally, perform rescue experiments in cells depleted of endogenous UEV1B using the various domain constructs to determine which domains are sufficient to restore normal endosomal sorting functions.

How can I design experiments to assess UEV1B antibody cross-reactivity with other UEV domain-containing proteins?

Designing rigorous experiments to assess UEV1B antibody cross-reactivity requires a systematic approach targeting the UEV domain homology challenge. Begin by expressing individual YFP-tagged constructs of UEV1A, UEV1B, and other UEV domain-containing proteins in cells with suitable morphology for microscopic analysis . Perform parallel Western blots and immunofluorescence studies using your UEV1B antibody alongside anti-YFP antibodies to directly compare detection patterns and identify potential cross-reactivity. For quantitative assessment, develop a peptide microarray containing overlapping peptides spanning the sequences of UEV1B and related proteins, particularly focusing on regions with high sequence similarity in the UEV domain and unique sequences in the B-domain . This allows epitope mapping and identification of cross-reactive epitopes. Implement competitive ELISAs where plates are coated with recombinant UEV1B and antibody binding is challenged with increasing concentrations of potential cross-reactive proteins. For in-cell validation, conduct sequential immunodepletion experiments where lysates are first cleared with antibodies against potential cross-reactive proteins before UEV1B detection. Additionally, leverage CRISPR/Cas9 technology to generate knockout cell lines for UEV1B and related proteins, providing definitive negative controls for antibody specificity testing across multiple immunological techniques.

How does post-translational modification of UEV1B affect antibody recognition and protein function?

Post-translational modifications (PTMs) of UEV1B significantly impact both antibody recognition and protein functionality in endosomal trafficking pathways. UEV1B can undergo various modifications including phosphorylation, ubiquitination, and potentially SUMOylation, each affecting protein conformation and interaction capabilities. For antibody recognition, phosphorylation of residues near the epitope can either enhance or inhibit antibody binding, creating potential false negatives in activation-dependent studies. To address this challenge, implement a parallel detection approach using phosphorylation-state specific antibodies alongside total UEV1B antibodies. For functional studies, systematically map PTM sites using mass spectrometry after immunoprecipitation of UEV1B from cells under various stimulation conditions. Generate phosphomimetic and phospho-dead mutants of identified sites to assess their impact on UEV1B's ability to colocalize with ubiquitin and Hrs in endosomes . The B-domain of UEV1B, which contains the endosomal targeting sequence , may be particularly subject to regulatory PTMs that control subcellular localization. Therefore, when designing experiments to study UEV1B function, consider how treatments that broadly affect cellular phosphorylation states (such as EGF stimulation) might simultaneously modify UEV1B's interactions with endosomal proteins. Finally, develop antibodies specifically recognizing modified forms of UEV1B to track how PTM patterns correlate with protein localization and function in endosomal sorting.

What computational models best predict UEV1B antibody epitopes for improved specificity?

Developing computational models to predict optimal UEV1B antibody epitopes requires integrating structural bioinformatics with experimental immunology data. Begin with sequence-based epitope prediction using algorithms that analyze parameters including hydrophilicity, surface accessibility, and antigenic propensity along the UEV1B sequence. Focus particularly on the B-domain region, which contains unique sequences not present in other UEV domain-containing proteins . For structural analysis, implement homology modeling of UEV1B's three-dimensional structure, with special attention to the novel endosomal targeting sequence within the B-domain . This model should inform surface accessibility calculations that identify epitopes likely to be exposed in the native protein. Recent advances in biophysics-informed modeling approaches for antibody specificity can be adapted specifically for UEV1B, allowing identification of distinct binding modes that enable discrimination between UEV1B and closely related proteins. The model should incorporate data from phage display experiments that select for antibodies with high specificity for UEV1B over related proteins . For validation, test computationally predicted epitopes through experimental approaches such as peptide arrays and competitive binding assays. Implement machine learning algorithms trained on experimental data from successfully specific antibodies to iteratively improve epitope predictions. This integrated approach combines the strengths of computational prediction with experimental validation to identify epitopes that maximize both specificity and accessibility in various experimental conditions.

How can live-cell imaging techniques be optimized for studying UEV1B dynamics in endosomal trafficking?

Optimizing live-cell imaging techniques for UEV1B dynamics requires overcoming several technical challenges specific to endosomal trafficking visualization. Begin by generating stable cell lines expressing UEV1B fused to photostable fluorescent proteins like mNeonGreen or HaloTag, which offer superior signal-to-noise ratio for endosomal tracking compared to traditional GFP. Since UEV1B strongly colocalizes with ubiquitin and Hrs in endosomes , implement dual-color imaging using spectrally distinct fluorophores for these proteins to track their dynamic interactions. To minimize phototoxicity while maintaining temporal resolution, utilize lattice light-sheet microscopy or spinning disk confocal systems with sensitive sCMOS cameras, allowing acquisition rates of 2-5 frames per minute for up to 60 minutes without significant photobleaching. For tracking individual endosomes containing UEV1B, implement automated particle tracking algorithms with Gaussian fitting for sub-pixel localization precision. When studying the impact of UEV1B on EGFR trafficking, use pH-sensitive fluorophores conjugated to EGF to distinguish between early endosomes, late endosomes, and lysosomes based on luminal pH. To correlate dynamic movements with functional outcomes, combine live-cell imaging with subsequent fixation and immunostaining in correlative light and electron microscopy (CLEM) approaches. Additionally, implement fluorescence recovery after photobleaching (FRAP) or photoactivation techniques to measure the exchange rate of UEV1B between cytosolic and endosome-bound pools, providing insight into the kinetics of association with endosomal structures.

What are the most effective strategies for detecting endogenous UEV1B in tissue samples for immunohistochemistry?

Detecting endogenous UEV1B in tissue samples through immunohistochemistry requires specialized approaches due to its endosomal localization and potential cross-reactivity challenges. Begin with antigen retrieval optimization, testing both heat-induced epitope retrieval (HIER) methods using citrate buffer (pH 6.0) and Tris-EDTA buffer (pH 9.0), as well as proteolytic-induced epitope retrieval using proteinase K. Since UEV1B strongly colocalizes with endosomal structures , its detection pattern should appear as discrete puncta rather than diffuse staining; validation should include comparison with endosomal markers such as EEA1 or LAMP1 in serial sections. To distinguish true UEV1B signal from background, implement tyramide signal amplification (TSA) which enhances sensitivity while maintaining specificity. For multiplex detection allowing simultaneous visualization of UEV1B with interaction partners like ubiquitin and Hrs , use multispectral imaging systems combined with spectral unmixing algorithms to separate closely overlapping fluorophores. To address potential cross-reactivity with other UEV domain-containing proteins, perform pre-absorption controls where the antibody is pre-incubated with recombinant UEV1B protein before tissue application. For quantitative analysis of UEV1B expression across different tissue types or disease states, develop automated image analysis pipelines that can identify and quantify endosomal puncta positive for UEV1B, allowing objective comparison between samples. Finally, validate tissue staining patterns using orthogonal techniques such as RNAscope in situ hybridization targeting UEV1B-specific transcripts.

Comparison Table of UEV1-Related Proteins and Their Characteristics